Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2011-01-11
2011-01-11
Szperka, Michael (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S141100, C424S141100, C424S152100, C424S805000
Reexamination Certificate
active
07867494
ABSTRACT:
The present invention relates to novel human antibodies specifically directed against human immunoglobulin E (anti-IgE). The present invention also relates to pharmaceutical compositions and methods for treating asthma, in particular allergic asthma, as well as other IgE-mediated disorders including allergic rhinitis and food allergies.
REFERENCES:
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5543144 (1996-08-01), Chang
patent: 5916771 (1999-06-01), Hori et al.
patent: 5939598 (1999-08-01), Kucherlapati et al.
patent: 5958708 (1999-09-01), Hardman et al.
patent: 5985615 (1999-11-01), Jakobovits et al.
patent: 5994619 (1999-11-01), Stice et al.
patent: 5998209 (1999-12-01), Jokobovits et al.
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 6091001 (2000-07-01), Jakobovits et al.
patent: 6114598 (2000-09-01), Kucherlapati et al.
patent: 6130364 (2000-10-01), Jakobovits et al.
patent: 6150584 (2000-11-01), Kucherlapati et al.
patent: 6162963 (2000-12-01), Kucherlapati et al.
patent: 6172213 (2001-01-01), Lowman et al.
patent: 6685939 (2004-02-01), Jardieu et al.
patent: 2005/0169909 (2005-08-01), Singh et al.
patent: WO91/10741 (1991-07-01), None
patent: WO91/17271 (1991-11-01), None
patent: WO92/01047 (1992-06-01), None
patent: WO92/09690 (1992-06-01), None
patent: WO92/15679 (1992-09-01), None
patent: WO92/18619 (1992-10-01), None
patent: WO 9217207 (1992-10-01), None
patent: WO92/20791 (1992-11-01), None
patent: WO93/01288 (1993-01-01), None
patent: WO93/06213 (1993-04-01), None
patent: WO94/02602 (1994-02-01), None
patent: WO96/33735 (1996-10-01), None
patent: WO96/34096 (1996-10-01), None
patent: WO98/16654 (1998-04-01), None
patent: WO98/24893 (1998-06-01), None
patent: WO98/50433 (1998-11-01), None
patent: WO98/52976 (1998-11-01), None
patent: WO99/45031 (1999-09-01), None
patent: WO99/53049 (1999-10-01), None
patent: WO00/09560 (2000-02-01), None
patent: WO00/34317 (2000-06-01), None
patent: WO00/37504 (2000-06-01), None
patent: WO03/048731 (2003-06-01), None
Portolano et al., J Immunol. Feb. 1, 1993;150(3):880-7.
Rudikoff et al., Proc Natl Acad Sci U S A. Mar. 1982;79(6):1979-83.
Janeway et al., Immunobiology, 3rdedition, 1997, Garland Press, pp. 3:7-3:11.
William E. Paul, M.D., editor, Fundamental Immunology, 3d ed. Raven Press, 1993, p. 242.
Babcook et al., A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities, Proc. Natl. Acad. Sci. USA 93:7843-7348 (1996).
Barbas et al., Assembly of combinatorial antibody libraries on phage surfaces: The gene III site, Proc. Natl. Acad. Sci. USA 88:7978-7982 (1991).
Bird et al., Single-chain antigen-binding proteins, Science 242:423-426 (1988).
Dibbern et al., RBL cells expressing human Fc epsilon RI are a sensitive tool for exploring functional IgE-allergen interactions: studies with sera from peanut-sensitive patients, J. Immunol Methods. 274(1-2):37-45 (2003).
Fuchs et al., Targeting recombinant antibodies to the surface ofEscherichia coli: fusion to a peptidoglycan associated lipoprotein, Bio/Technology 9:1370-1372 (1991).
Garrad et al., Fab assembly and enrichment in a monovalent phage display system, Bio/Technology 9:1373-1377 (1991).
Gram et al., In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library, Proc. Natl. Acad. Sci. USA 89:3576-3580 (1992).
Green and Jakobovits, Regulation of B cell development by variable gene complexity in mice reconstituted with human immunoglobulin yeast artificial chromosomes, J. Exp. Med. 188:483-495 (1998).
Green et al., Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs, Nature Genetics 7:13-21 (1994).
Griffiths et al., Human anti-self antibodies with high specificity from phage display libraries, EMBO J. 12:725-734 (1993).
Hawkins et al., Selection of phage antibodies by binding affinity. Mimicking affinity maturation, J. Mol. Biol. 226:889-896 (1992).
Hay et al., Bacteriophage cloning andEscherichia coliexpression of a human IgM Fab, Hum. Antibod. Hybridomas 3:81-85 (1992).
Holliger et al., “Diabodies”: small bivalent and bispecific antibody fragments, Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993).
Hoogenboom et al., Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains, Nuc. Acid Res. 19:4133-4137 (1991).
Huse et al., Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda, Science 246:1275-1281 (1989).
Huston et al., Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced inEscherichia coli, Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988).
McCafferty et al., Phage antibodies: filamentous phage displaying antibody variable domains, Nature 348:552-554 (1990).
Mendez et al., Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice, Nature Genetics 15:146-156 (1997).
Poljak et al., Production and structure of diabodies, Structure 2:1121-1123 (1994).
Presta et al., Humanization of an antibody directed against IgE, J. Immunol. 151(5):2632-2632 (1993).
Tabcharani et al., Phosphorylation-regulated Cl- channel in CHO cells stably expressing the cystic fibrosis gene, Nature 352:624-628 (1991).
Wiegand et al., High-affinity oligonucleotide ligands to human IgE inhibit binding to Fc epsilon receptor I, J. Immunol. 157(1):221-230 (1996).
Beyaz-Kavuncu Nurten
Brown Caroline
Casperson Gerald F.
de Mendez Isabelle
Diaz-Collier Judith
Amgen Fremont Inc.
Pfizer Inc.
Ropes & Gray LLP
Szperka Michael
LandOfFree
Anti-IgE antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-IgE antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-IgE antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2642689